Cargando…

Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial

BACKGROUND: Secondary hyperparathyroidism is a common complication of chronic kidney disease and is managed using vitamin D replacement therapy. Very few studies have examined the effectiveness of pulse alfacalcidol therapy in comparison to daily oral alfacalcidol therapy in suppressing serum parath...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawalmeh, Osama, Moala, Shaheed, Hamdan, Zakaria, Masri, Huda, Ayoub, Khubaib, Khazneh, Emad, Shraim, Mujahed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774473/ https://www.ncbi.nlm.nih.gov/pubmed/29391823 http://dx.doi.org/10.2147/IJNRD.S149877

Ejemplares similares

The effects of Ramadan fasting on clinical and biochemical markers among hemodialysis patients: A prospective cohort study
por: Khazneh, Emad, et al.
Publicado: (2019)

Single-dose baclofen-induced neurotoxicity in a patient with end stage renal disease: case report
por: Khazneh, Emad, et al.
Publicado: (2018)

Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients
por: Lessard, Myriam, et al.
Publicado: (2014)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Pathological right ventricular changes in synthesized electrocardiogram in end-stage renal disease patients and their association with mortality and cardiac hospitalization: a cohort study
por: Daralammouri, Yunis, et al.
Publicado: (2022)

Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
por: Dörr, Katharina, et al.
Publicado: (2023)

Epidemiology of Common Ocular Manifestations among Patients on Haemodialysis in West Bank, Palestine
por: Shanti, Yousef, et al.
Publicado: (2023)

Quality of life for kidney transplant recipients and hemodialysis patients in Palestine: a cross-sectional study
por: Sarhan, Adnan Lutfi, et al.
Publicado: (2021)

Early bioprosthetic valve calcification with alfacalcidol supplementation
por: Takano, Tamaki, et al.
Publicado: (2013)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

Alfacalcidol enhances collagen quality in ovariectomized rat bones
por: Nagaoka, Hideaki, et al.
Publicado: (2014)

Bone mineral density in Palestinian patients with end-stage renal disease and the related clinical and biochemical factors: Cross-sectional study
por: Nazzal, Zaher, et al.
Publicado: (2020)

Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism
por: El-kholey, Mohamed Mimi Abd Elgawwad, et al.
Publicado: (2019)

Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Peroxygenase-Catalyzed Selective Synthesis of Calcitriol Starting from Alfacalcidol
por: Li, Yuanying, et al.
Publicado: (2022)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group Study
por: Matuszkiewicz-Rowińska, Joanna, et al.
Publicado: (2022)

Quality of life in hemodialysis diabetic patients: a multicenter cross-sectional study from Palestine
por: Khatib, Sohaib T., et al.
Publicado: (2018)

Quantification of Alfacalcidol Tablets Dissolution Content by Chemical Derivatization and LC-MS
por: Liu, Yang, et al.
Publicado: (2020)

Parathyroidectomy Is Associated with Reduced Mortality in Hemodialysis Patients with Secondary Hyperparathyroidism
por: Ma, Tsung-Liang, et al.
Publicado: (2015)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.
por: Raina, V., et al.
Publicado: (1991)

Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis
por: Diao, Zongli, et al.
Publicado: (2016)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

Fibrous dysplasia in maxilla in a patient on hemodialysis with severe secondary hyperparathyroidism
por: Yang, Hui-Hsin, et al.
Publicado: (2022)

Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial
por: Ni, Xiaolin, et al.
Publicado: (2021)

Hypercalcemia due to Co-Occurring Metastatic Breast Cancer and Primary Hyperparathyroidism
por: Khubaib, Mohammad U, et al.
Publicado: (2021)

Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial
por: Oka, Tatsufumi, et al.
Publicado: (2022)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
por: Tokumoto, Masanori, et al.
Publicado: (2022)

Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
por: Qiu, Wenqiang, et al.
Publicado: (2023)

Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial
por: Iseki, Kunitoshi, et al.
Publicado: (2022)

Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
por: Fang, Li, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_82jl86s057etmc6flscin9kjsb